Lilly Has Moved from Warnings to Litigation
On August 12, 2026, Eli Lilly filed six lawsuits against U.S companies for allegedly selling or facilitating access to unauthorized retatrutide products.[1] The defendants are Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co, and span several parts of the market, including online peptide sellers, a pharmacy and a medical spa business.
In addition, Lilly says it has referred information concerning more than 200 individuals and entities to FDA, U.S. Department of Justice, state attorneys general, law enforcement agencies and professional licensing boards, and is seeking assistance from platforms and other commercial intermediaries, including payment processors and shipping companies, in disrupting unauthorized sales.
The significance extends beyond the six named defendants. Lilly’s actions suggest that the enforcement perimeter is moving beyond the company that directly sells a product to the broader ecosystem that enables the product to reach the market. For companies operating in the peptide, compounding, telehealth, medical spa, wellness or weight management sectors, the practical question is, therefore, not simply whether a particular product is lawful, but whether the overall business model – and the company’s role within the supply chain – can withstand scrutiny from FDA, state regulators, private litigants and commercial partners.
FDA Enforcement is Already Underway
Lilly’s lawsuits are not occurring in a regulatory vacuum. FDA has previously warned companies concerning the distribution and marketing of retatrutide and other unapproved GLP-1 products.[2] FDA’s current materials also note that the agency has issued warning letters to companies distributing active pharmaceutical ingredients such as retatrutide, and to telehealth companies marketing unapproved drugs. The agency has expressly stated that “retatrutide and cagrilintide cannot be used in compounding under federal law”, and that neither is a component of an FDA-approved drug.
The significance is broader than any individual warning letter. FDA’s enforcement activity, combined with Lilly’s litigation campaign, points toward a market in which companies should expect greater scrutiny of the entire path from product sourcing to consumer marketing and distribution.
Two Enforcement Tracks Are Converging
Companies in this market should distinguish between FDA enforcement risk and private litigation risk.
FDA’s concerns arise under the Federal Food, Drug & Cosmetic Act, including issues involving unapproved new drugs, misbranding, impermissible compounding and evidence of intended use. Lilly’s lawsuits, by contrast, represent private litigation by the manufacturer seeking to protect its product and commercial interests. Those risks are distinct, but they can arise from the same underlying business practices. A company responding to a manufacturer demand therefore should not assume that the issue is solely a private dispute. Similarly, an FDA inquiry may warrant consideration of potential private party exposure.
The practical lesson is important: a demand letter, regulatory inquiry, payment interruption, platform restriction, or other intervention should be evaluated not only as an isolated event, but as a potential signal of a broader compliance vulnerability.
Retatrutide Is Not Another Compounded GLP-1
Unlike approved GLP-1s, retatrutide remains investigational and is in Phase 3 clinical development, with Lilly saying it plans to submit the drug for FDA review in Q1 2027. [3],[4] That timing makes FDA’s position on compounding particularly important because unapproved drugs cannot be used in compounding under federal law – which means the regulatory history of semaglutide and tirzepatide, which can be legally compounded, should not be assumed to provide a roadmap for retatrutide. The statutory requirements applicable to compounding under Sections 503A and 503B remain critical to any analysis of whether a particular compounded drug qualifies for the applicable statutory exemptions.
For companies considering adding retatrutide or another investigational peptide to an existing product or service offering, this distinction should be addressed ideally before the commercial model is launched, but if afterwards, then existing sourcing, marketing and distribution arrangements should be evaluated.
“Research Use Only” Labeling Is Not the Last Word On Intended Use
One of the most important lessons from FDA’s enforcement activity is that labels do not determine intended use; the totality of the company’s conduct does.
FDA has repeatedly applied this principle to retatrutide and other peptides. For example, in March 2026, FDA concluded that retatrutide, marketed by Gram Peptides, was an unapproved new drug despite “RUO” and “not intended for human consumption, medical use, or veterinary use” statements on the product labeling.[5] FDA pointed to the company’s website and specific claims concerning appetite suppression, body weight, glucose handling, lipid metabolism and related effects as evidence of intended use.
Therefore, for companies selling peptides, a research-use disclaimer therefore should not be treated as a regulatory safe harbor if other aspects of the business point in the opposite direction. FDA may consider:
- website and product page content;
- weight loss, metabolic or other therapeutic claims;
- social media posts and advertising;
- dosing instructions or protocols;
- customer communications;
- product presentation and labeling;
- relationships with healthcare providers or pharmacies; and
- the company’s broader commercial practices.
The question is not simply what the company says the product is for, but rather what the company’s overall conduct can tell FDA about the product’s intended use.
The Regulatory Perimeter Extends Through the Supply Chain
FDA’s actions involving API distribution are particularly instructive. In September, 2025, the agency began issuing over 50 warning letters to companies distributing active pharmaceutical ingredients, including where the agency determined that the products were being supplied to pharmacies seeking to compound human drugs.[6]
At the other end of the commercial chain; FDA has increasingly focused on how telehealth companies and other businesses market and facilitate access to compounded and unapproved GLP-1 products, issuing 55 warning letters in 2026 over two waves in March and June.[7]
For businesses in this market, the relevant question may therefore be not only: “What are we selling?”
but also: “What are we enabling others to do?”
That distinction is particularly important for businesses that do not consider themselves drug manufacturers or compounders, but provide products or services to companies that are.
Who Should Be Paying Attention?
The current enforcement environment should be on the radar of:
- Peptide and API manufacturers and distributors
- 503A pharmacies and 503B outsourcing facilities
- Telehealth and digital health companies
- Medical spas and weight management practices
- Companies selling products characterized as “research use only”
- Businesses providing fulfillment, marketing, technology, payment or other services to these companies
For each of these businesses, the regulatory analysis should begin well before a finished drug reaches a patient.
What Companies Should Do Now
Companies entering or already operating in the peptide and GLP-1 markets should consider a targeted regulatory assessment of the business model itself.
Four questions should be at the center of that review:
What are you selling, and where did it come from?
Identify the peptides and other drug substances being sold, distributed, compounded or incorporated into services. Assess their regulatory status, sourcing, quality controls and supply chain relationships.
What does your conduct tell FDA about intended use?
Review websites, product pages, social media, advertising, labeling, customer communications, dosing information and other materials. A research-only disclaimer should not be viewed in isolation.
What is your business enabling downstream?
Evaluate relationships with pharmacies, prescribers, telehealth companies, distributors, fulfillment providers and other commercial partners. Consider what the company knows – or reasonably should know – about downstream use.
Could you defend the model if FDA or the manufacturer scrutinizes it tomorrow?
Assess applicable federal and state requirements, contractual protections, compliance controls, documentation and an escalation plan for FDA inquiries, warning letters, manufacturer demands, payment interruptions or platform restrictions. Companies contemplating a new peptide or GLP-1 offering should conduct this assessment ideally before launch, but if already underway, then retrofit compliance as necessary given the established business model and commercial relationships.
Looking Ahead
The retatrutide lawsuits are significant even for businesses that do not currently sell retatrutide. They illustrate a broader convergence of FDA enforcement, manufacturer-led litigation and commercial pressure on the infrastructure supporting unauthorized products. With many manufacturers having new peptides and other drug products in the pipeline, scrutiny of unauthorized versions and the businesses supporting their distribution is likely to escalate from here. For companies considering entering, expanding or already operating in this market, there is value in pressure testing the model before FDA or a competitor does it for you. Vedder’s FDA Regulatory Strategy & Compliance practice advises pharmaceutical, biotechnology, compounding, telehealth, medical spa, wellness and other life sciences companies on FDA requirements, product and promotional strategies, supply chain arrangements and practical compliance programs in rapidly evolving markets.
[1] https://www.law360.com/articles/2512795/lilly-claims-6-vendors-illegally-sold-obesity-drug-candidate
[2] https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[3] https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
[4] https://www.cnbc.com/2026/07/23/eli-lilly-will-file-for-approval-of-retatrutide-obesity-drug-in-2027.html?msockid=366a1bb7b452610c03060cd6b58760d9
[5] https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
[6] https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
[7] https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
